Head-to-head comparison
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~6 days | ~5 days |
| Mol. Weight | 4,894.58 Da | 4,813.45 Da |
| Side Effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Receptor targets: Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist.
- Weight loss efficacy: Phase II data showed retatrutide (12 mg) achieved approximately 24% weight loss at 48 weeks; tirzepatide (15 mg) achieved 22.5% at 72 weeks in Phase III SURMOUNT trials.
- Glucagon component: Retatrutide's glucagon receptor agonism increases energy expenditure and hepatic fat oxidation, a mechanism tirzepatide lacks.
- Approval status: Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity); retatrutide is in Phase III clinical trials with no approval yet.
- Manufacturer: Retatrutide is developed by Eli Lilly, the same company behind tirzepatide, suggesting a potential pipeline succession.
- Liver fat reduction: Retatrutide Phase II data showed significant liver fat reduction, potentially relevant for MASH/NAFLD; tirzepatide also shows liver fat benefits but through fewer receptor pathways.
- Safety profile: Retatrutide Phase II showed GI side effects similar to tirzepatide; long-term Phase III safety data is pending.
The verdict
Retatrutide's Phase II data suggests it may eventually surpass tirzepatide as the most effective weight loss peptide, with the added glucagon receptor providing metabolic benefits tirzepatide lacks. However, tirzepatide is FDA-approved and commercially available today with extensive Phase III safety data, while retatrutide is still in trials. For current clinical use, tirzepatide is the established option; retatrutide represents the next frontier if Phase III results confirm the Phase II promise.
Frequently asked questions
Phase II data suggests retatrutide may produce greater weight loss (approximately 24% at 48 weeks vs tirzepatide's 22.5% at 72 weeks), but direct comparison is limited by different trial designs. Phase III results will provide clearer evidence. Tirzepatide has confirmed Phase III efficacy data; retatrutide does not yet.
Retatrutide is currently in Phase III clinical trials conducted by Eli Lilly. If trials succeed, FDA approval could follow, but specific timelines are not confirmed. Tirzepatide is available now by prescription.
The glucagon receptor component increases energy expenditure and stimulates hepatic fat oxidation, potentially providing additional weight loss and liver fat reduction beyond what GLP-1/GIP dual agonism achieves alone. This is the key differentiator from tirzepatide.
Yes, both are developed by Eli Lilly. Retatrutide is positioned as a potential next-generation therapy that could succeed or complement tirzepatide in Lilly's obesity pipeline.
Phase II data showed similar GI side effect profiles (nausea, vomiting, diarrhea). The glucagon component raises theoretical concerns about hepatic effects, but Phase II safety data was acceptable. Comprehensive safety comparison requires Phase III data, which is ongoing.